The proteasome is a sophisticated, 2.5-MDa, multisubunit complex that contains a catalytic core particle (CP) and two terminal regulatory particles (RPs); the RPs associate with the termini of the central CP at opposite orientations. The CP consists of four axially stacked heptameric rings (two outer α-rings and two inner β-rings), which are made up of seven structurally related, but not identical, α and β subunits. The CP contains catalytic threonine residues (in β1, β2, and β5 with caspase-like, trypsin-like, and chymotrypsin-like activities, respectively) on the surface of the chamber formed by two abutting β-rings. The RP recognizes polyubiquitylated substrate proteins and unfolds and translocates these proteins to the interior of the CP for degradation. The RP comprises 19 different subunits, which are thought to form two subcomplexes called the lid and the base. One longstanding question is how the complex structure of the proteasome is organized with high fidelity. Recently, we proposed a novel assembly mechanism that is assisted by multiple proteasome-dedicated chaperones. In addition, we discovered two immuno-type proteasomes, the immunoproteasome and the thymoproteasome, whose catalytic subunits are replaced by homologous counterparts. These two isoforms perform specialized functions that help discriminate self from non-self in cell-mediated immunity (i.e., they function as enzymes that process intracellular antigens for cytotoxic T lymphocyte responses and thymic positive selection). Moreover, emerging evidence suggests that the proteasome is crucially involved in the pathophysiology of various intractable diseases that are increasing in today's aging society.
Introduction
In accordance with the second law of thermodynamics, in living organisms, energy produced by ATP hydrolysis was believed to be exclusively required for biosynthetic reactions, but not for degradative reactions. However, in 1953, Simpson showed that metabolic energy is required for proteolysis in living cells by measuring the release of amino acids from radio-labeled proteins in rat liver slices. 1 This surprising result then remained largely unexplored because of its counterintuitive nature. However, in 1977, Goldberg's laboratory focused attention on Simpson's hypothesis by identifying an ATP-dependent proteolytic pathway in rabbit reticulocyte extracts, 2 in which ATP hydrolysis (i.e., the consumption of energy) greatly stimulated protein breakdown in vitro. This finding helped open a new area of research in extra-lysosomal proteolysis pathways in eukaryotes. Remarkably, the following year, Hershko's group identified a small heatstable protein named ATP-dependent proteolysis factor (AFP-1), which was subsequently found to be identical to ubiquitin. 3 By the early 1990s, the delineated ubiquitin hypothesis, which proposed that ubiquitin functions as a degradation signal by covalent attachment to a target protein through an energy-dependent mechanism, had developed significantly (reviewed by Hershko and Ciechanover 4, 5 ). Studies on the ubiquitin system have since clarified the molecular mechanistic actions 6, 7 and addressed the importance of the pathophysiological roles of this system. 8, 9 The importance of this discovery was highlighted when the 2004 Nobel Prize in Chemistry was awarded jointly to Aaron Ciechanover, Avram Hershko, and Irwin Rose for the discovery of ubiquitin-mediated protein degradation.
I joined Goldberg's laboratory in 1981, and during my 2 years in Boston, I was able to demonstrate a new energy-dependent mechanism in proteolysis, in which ATP serves two distinct roles in protein degradation in reticulocytes: one which requires ubiquitin and one that is independent of ubiquitin. 10 A second, ubiquitin-independent energy-requiring step was further clarified by the discovery of a eukaryotic ATP-dependent protease, called the proteasome, that selectively degrades ubiquitin-tagged proteins (reviewed by Finley, 7 Coux et al., 11 and Baumeister et al. 12 ). The proteasome is a large and complex proteolytic machine that regulates a variety of physiologically and pathologically important cellular processes by selectively breaking down unnecessary proteins in eukaryotes 13 (Fig. 1) . We recently reviewed the pathophysiology of the proteasome in vivo, with particular emphasis on mammals. 14 In addition, many excellent comprehensive review articles have been recently published on the dynamic aspects and mechanistic actions of the ubiquitin−proteasome system (for details, see Dohmen et al. 15 )
Basic Mechanisms

Core particle
The catalytic core particle (CP, also known as the 20S proteasome) is a well-organized multisubunit complex of about 750 kDa. Based on electron microscopy (EM) and quaternary structure analyses by X-ray crystallography, the overall configuration of the CP is conserved in various eukaryotes from yeast to mammals. 16, 17 The CP is barrel shaped as a result of the axial stacking of two outer α-rings and two inner β-rings. These rings respectively comprise seven structurally similar α and β subunits, resulting in an α 1 − 7 β 1 − 7 β 1 − 7 α 1 − 7 structure (Fig.  2, left panel) . Of the seven β-type subunits that make up the inner β-rings, three types (β1, β2, and β5) contain catalytically active threonine residues at their N termini and show N-terminal nucleophile hydrolase activity that cleaves peptide bonds. The β1, β2, and β5 subunits are associated with caspase-like, trypsin-like, and chymotrypsin-like activities, respectively, that cleave peptide bonds at post-acidic, -basic, and -hydrophobic amino-acid residues, respectively. Two pairs of these three active sites reside in the chamber formed by the two abutting β-rings, facing the interior of the cavity. Its multifaceted features and proteolytic specificities indicate that the proteasome can rapidly hydrolyze substrate proteins through an exhaustive or limited digestion mechanism (see below).
The crystal structure of the CP reveals that the center of the α-ring is almost completely closed, preventing substrate proteins from penetrating into the inner cavity of the β-ring where the proteolytically active sites are located. Indeed, the N-termini of the α subunits form a physical barrier that prevents substrate proteins from accessing the active sites in the β-ring, indicating that the CP is latent in cells. Thus, a substrate is able to access the active sites only after passing through a narrow opening in the closed gate at the center of the α-rings. 
Regulatory particles
The regulatory particle (RP) was initially found biochemically to serve as a proteasome activator and to have a molecular mass of approximately 700,000 (it is often called PA700). Two symmetrically disposed RPs (whose exact sizes are 900 kDa each) are attached to the ends of the central CP to form the so-called 26S proteasome, although its correct sedimentation coefficient determined by a physical technique is approximately 30S; the 26S proteasome is likely the functional unit that selectively digests a wide array of polyubiquitylated substrate proteins in eukaryotic cells. 14 The RP recognizes polyubiquitylated proteins, deubiquitylates these proteins to recycle the ubiquitin moieties, and then unfolds and translocates the proteins into the interior of the CP (Fig. 3) . Moreover, the RP is also involved in opening the α-ring that forms the closed gate of the CP. Thus, the RP essentially contributes to the above-mentioned four steps that occur prior to the destruction of target proteins by the CP.
The RP consists of a set of distinct integral subunits that can be subclassified into two groups: a regulatory particle of six triple-ATPase (Rpt) subunits and a regulatory particle of thirteen non-ATPase (Rpn) subunits. The RP can be separated into two subcomplexes: the lid and the base. The base includes six different AAA+ ATPase subunits (Rpt1−Rpt6) and three non-ATPase subunits (Rpn1, Rpn2, and Rpn13), while the lid consists of nine non-ATPase subunits (Rpn3, 5−9, 11, 12 and 15). 13 The concept of the lid and base was founded on biochemical studies in which these subcomplexes could be easily and consistently isolated from extracts of yeast that genetically lacked the Rpn10 subunit. 18 Accordingly, it has been long assumed that the Rpn10 subunit connects the base to the lid and stabilizes this complex. Intriguingly, a recent single-particle analysis using cryo-EM revealed that Rpn10 and Rpn13 are located at a distant site on the apical part of the RP complex near the periphery 19 (see Fig. 3 ). This orientation is rational because both subunits serve as ubiquitin receptors; Rpn10 and Rpn13 function The active threonine residues in β1, β2, and β5 appear in blue, purple, and red, respectively. For details, see Unno et al. 17 Middle panel, model of immuno-type proteasome isoforms. The standard proteasome (top), immunoproteasome (middle), and thymoproteasome (bottom) are depicted. Right panel, diagrams of the electrostatic surface potential of the S1 pockets for the chymotryptic active sites of the standard proteasome (top), immunoproteasome (middle), and thymoproteasome (bottom). The surface is colored according to the electrostatic potential (blue, positive; red, negative). The catalytic threonine residue is surrounded by a dotted circle (top panel). The models of the immunoproteasome and thymoproteasome were predicted from standard structures.
as integral ubiquitin receptors that efficiently trap polyubiquitylated substrates, which is required for the initial stage of degradation. Indeed, Rpn10 achieves this function via a C-terminal ubiquitin-interacting motif (UIM). In contrast, the N-terminal domain of Rpn13 shows no homology to known ubiquitin-binding motifs, but instead contains a novel pleckstrin-like receptor for ubiquitin (Pru) domain. 20, 21 The Pru domain in human Rpn13 shows high affinity for diubiquitin. 22 To date, in contrast to yeast and mammalian 20S CPs, all efforts to define the atomic structure of the 26S holoproteasome have failed, presumably because of the fragile nature and dynamics of the RP complex. Nevertheless, very recently, two groups independently delineated the complete subunit architecture of the RP using cryo-EM, X-ray crystallography of the individual subunits, residuespecific chemical cross-linking, and a new heterologous expression system for the lid, and provided insight into the sequence of events prior to the degradation of polyubiquitylated substrates 23, 24 (Fig. 3) . One function of the lid is to deubiquitylate captured substrates, a process in which the metalloisopeptidase Rpn11 helps recycle the ubiquitin. 25 Importantly, Rpn11 deubiquitylating enzyme (DUB) cleaves the polyubiquitin chain at a site proximal to the substrate, coupled with substrate degradation. Rpn11 was found to be located near the substrate entry position in the ATPase ring, elucidating how the polyubiquitin chain is cleaved just before the substrate is incorporated into the Rpt complex channel. In addition, in mammalian cells, two DUBs [Usp14 and Uch37 (also known as UCHL5)] that are physically associated with the base complex sequentially cleave the ubiquitin moiety at a distal site to the substrate and regulate protein degradation. 26, 27 Usp14 (equivalent to yeast Ubp6) is directly associated with Rpn1, and Uch37 binds to the base Rpn2 via Rpn13. 13 Interestingly, the C-terminal domain of Rpn13 stimulates the deubiquitylating activity of Uch37 that is found only in higher eukaryotes, which seems to collaborate with the N-terminal ubiquitin receptor site to facilitate proteolysis. In addition, it was recently found that the subunit Rpn6 with as-yet-unknown function plays a pivotal role in stabilizing the otherwise weak interaction between the CP and the RP. 28 Considering these follow-up studies, it is noteworthy that the aforementioned RP architecture is not compatible with the notion of base and lid subcomplexes of the RP, and thus these concepts should be reconsidered.
The base complex is composed of six homologous AAA-ATPase subunits (Rpt1−Rpt6) forming a crownlike shape, and three non-ATPase subunits (Rpn1, Rpn2, and Rpn13). The ATPase ring serves the following three functions: (1) it promotes substrate unfolding after the Rpt ring pulls substrates into the central pore, (2) it opens the channel in the closed α-ring, and (3) it translocates the substrates into the CP, thus enhancing their destruction. [29] [30] [31] Among the six Rpt subunits, only Rpt2, Rpt3, 19 and Rpt5 contain a C-terminal hydrophobic-tyrosine-X (HbYX) motif, and the Rpt2 and Rpt5 subunits specifically facilitate the opening of the CP gate. 14 However, it is noteworthy that the energy generated by the Rpt ring is sufficient to promote unfolding of substrate structure domains, but not for any other processes mediated by the RP, i.e., ATP is utilized only to unfold the target proteins. Further studies are required to determine the crystal structures of the RP and/or the 26S proteasome to understand at the atomic resolution how the proteasome mechanistically catalyzes the destruction of target proteins.
Assembly
A growing body of evidence has revealed the molecular mechanisms underlying proteasome assembly (reviewed by Murata et al., 32 Tomko and Hochstrasser, 33 and Saeki and Tanaka 34 ). One important goal is to discover a restricted set of proteasome-dedicated assembling chaperones that assist in CP formation. First, we identified four novel chaperones, named proteasome assembly chaperone (PAC) 1−4 in mammals, that assist in α-ring formation; all four were subsequently identified in yeast. These chaperones form a pair of functional heterodimers, PAC1-PAC2 and PAC3−PAC4. 32, 33 Although the PAC1− PAC2 and PAC3−PAC4 complexes perform distinct roles in the assembly pathway, they cooperate in the efficient assembly of α-rings. Intriguingly, knocking down PAC1 and/or PAC2 expression in mammalian cells decreases the number of α-rings and results in the accumulation of abnormal products that cause unusual α-ring dimers, implying that the PAC1−PAC2 complex prevents accidental formation of non-productive intermediates (i.e., off-pathway assembly). In contrast, the PAC3−PAC4 complex was found to specifically bind the α5 subunit. Additional co-crystal structure and mutational analyses revealed that this complex helps to successively bind the neighboring subunits, contributing to the ordered assembly of α-ring subunits.
After completion of α-ring assembly, the β subunits are incorporated onto the α-ring at the correct positions in a defined order, forming the 20S proteasome (reviewed by Murata et al. 32 ). Indeed, we clarified the mechanism by which β-rings form on α-rings by characterizing assembly intermediates that accumulated in mammalian cells in which each β subunit was successively knocked down. Starting from β2, incorporation of the other β subunits occurs in an orderly manner that depends on the propeptides of β2 and β5 and the β2 C-terminus, which function as so-called intramolecular chaperones. Unexpectedly, Ump1 (also called POMP, proteasome maturation protein, or proteassemblin), which is a chaperone that functions at the final assembly step in yeast, is incorporated as early as β2 and is required for the structural integrity of early assembly intermediates in mammals. Based on these findings, we proposed a model in which β-ring formation is assisted by both intramolecular and extrinsic chaperones. 32 Knocking down PAC1 does not cause complete loss of the CP in mammalian cells, suggesting the presence of both chaperone-dependent and -independent assembly pathways, although the contribution of the chaperonedependent pathway remains unclear. To elucidate the physiological significance of PAC1-mediated proteasome assembly in vivo, we generated PAC1-conditional knockout (KO) mice in which this chaperone is systemically deleted. 35 In-depth studies revealed that the absence of PAC1 was embryonically lethal and PAC1-null mice died at approximately E6.0. The half-life of PAC1 is approximately 30−40 min, and the PAC1 protein was almost completely lost within a few hours in PAC1-KO cells, and thus PAC1 was also soon lost in the experimental setting in vivo. However, this phenotype is still milder than that of mice deficient in the proteasome base ATPases Rpt3 and Rpt5; such mice died before they developed into blastocysts (~E3.5). Accordingly, proteasome biogenesis is not entirely dependent on the PAC1 assembly chaperone, and a PAC1-independent assembly pathway also operates during embryogenesis. Nonetheless, efficient PAC1-based proteasome biogenesis is required for development beyond the blastocyst stage and thus is essential for late embryonic development in mice, which require a large number of proteasomes. Brain-specific PAC1-deficient mice exhibited a large decrease in the levels of both 20S and 26S proteasomes after birth, which resulted in severely impaired development of the central nervous system, particularly in the cerebellum, which develops significantly after birth. Taken together, the study clearly demonstrated that PAC1 is essential for mammalian development, especially for explosive cell proliferation. In contrast, PAC1 is also responsible for producing the majority of CPs in the liver, where hepatocytes are normally quiescent. 35 Free latent CPs almost completely disappeared several weeks after PAC1 ablation, but, surprisingly, the levels of the 26S proteasome remained unchanged for at least 6−12 months under PAC1-deficient conditions, indicating that normal 26S proteasome levels were potentially maintained by efficient production in a PAC1-independent assembly pathway. However, mice lacking PAC1 in the liver exhibited premature senescence, suggesting that chaperone-assisted proteasome biogenesis is essential to maintain homeostasis in the liver. These findings indicate the physiologically important roles of the PAC1-dependent assembly pathway in rapidly proliferative cells and of PAC1, and thereby the CP itself, in the maintenance of cell integrity in quiescent cells.
Base assembly is also a highly organized process and is assisted by four base-dedicated chaperone proteins: Nas2/ p27, Nas6/gankyrin/p28, Rpn14/PAAF1, and Hsm3/S5b (yeast/human: miscellaneous nomenclature). [33] [34] [35] Recent studies have proposed renaming Rpn14, Nas6, Nas2, and Hsm3 as RP assembling chaperones (RACs), or RAC1, 2, 3, and 4, respectively. 33 Intriguingly, precursor intermediates consisting of two pairs of Rpt subunits with appropriate specific chaperone(s) (notably the RAC3−Rpt5− Rpt4, RAC2−Rpt3−Rpt6−RAC1, and RAC4−Rpt1−Rpt2 complexes) are formed prior to ATPase ring assembly. Among these, RAC1 transiently binds to the C-terminal domain of the Rpt6 subunit (Rpt6-C) during maturation of the ATPase ring. The crystal structure of yeast RAC1 revealed that the top face of RAC1 has a highly acidic surface, whereas the putative interacting surface of Rpt6-C is basic, suggesting that there are complementary charge interactions between these two proteins, 36 as observed in the interaction between RAC2 and Rpt3-C. 37 On the other hand, RAC4 transiently binds to the C-terminal domain of the Rpt1 subunit and forms a tetrameric complex, RAC4−Rpt1−Rpt2−Rpn1, during maturation of the ATPase ring of the RP. Moreover, the crystal structure of RAC4 revealed that it has a C-shaped structure consisting of 11 HEAT repeats. 38 The structure of the RAC4−Rpt1−C complex revealed that the interacting surface between RAC4 and Rpt1 is a hydrophobic core and complementary charged surface. Mutations in the RAC4−Rpt1 surface resulted in an assembly defect in the 26S proteasome. Furthermore, a structural model of the RAC4−Rpt ring complex and an in vitro binding assay suggest that RAC4 can bind to Rpt2 in addition to Rpt1. Moreover, we recently used a quantitative proteomics approach to determine the near stoichiometric binding of Ubp6 to the base precursor(s) of the RP as well as to the mature 26S proteasome and determined that Ubp6 facilitates proteasomal assembly by clearing polyubiquitylated substrates from assembly precursors through its deubiquitylating activity. 39 
Regulation
Currently, it is thought that genes encoding proteasome components, including many proteasome-interacting proteins (PIPs), comprise approximately 0.5% of all genes in the human genome, indicating that these proteins have tremendous biological importance. Despite their potential importance, the mechanisms controlling proteasome regulation were not fully addressed until recently. One longstanding question was how proteasome expression is maintained or regulated based on changes in the intracellular and/or environmental conditions. In yeast, it was established that the transcription factor Rpn4 is a transcriptional activator that binds to the promoters of proteasome genes and is required for proteasome gene expression. 40, 41 Interestingly, Rpn4 is extremely short-lived, and it is rapidly degraded by the 26S proteasome with a half-life (t 1/2 ) of approximately 2 min, indicating that there is a feedback circuit that homeostatically controls the proteasome.
A similar transcriptional feedback loop for proteasome regulation is also conserved in mammals. Surprisingly, erythroid-derived 2-related factor 1 (Nrf1; also named TCF11), which is a basic leucine zipper transcription factor that mediates cellular responses to many xenobiotic and pro-oxidant stresses, was shown to be necessary to induce proteasome gene transcription. 42, 43 Thus, Nrf1 is assumed to be a functional yeast Rpn4 counterpart in mammalian cells, although there are no obvious structural similarities. Under physiological conditions, Nrf1 is targeted to the endoplasmic reticulum (ER), implying that it is translocated into the nucleus in response to an activating signal. Nrf1 is targeted for ER-associated protein degradation (ERAD) through a process that requires the E3 ubiquitin ligase HRD1. Proteasome inhibitors trigger the accumulation of oxidant-damaged proteins and promote the nuclear translocation of Nrf1 from the ER, permitting activation of proteasome gene expression by binding to antioxidant response elements in their promoter regions, indicating that a transcriptional control loop regulates human proteasome-dependent protein degradation to counteract proteotoxic stress caused by proteasome inhibition.
In addition, Nrf1 is currently thought to be controlled at multiple post-translational steps, including ubiquitylation, proteolytic processing, and proteasome-mediated degradation, as well as by phosphorylation. Intriguingly, β-TrCP, an adaptor for the Skp1-Cul1-F-box protein (SCF) ubiquitin ligase, promotes Nrf1 degradation by catalyzing its polyubiquitylation in the nucleus. 44 On the other hand, it has also been reported that Nrf1 is a shortlived protein that is targeted by the F-box protein Fbw7, which is another substrate-specifying component of SCFtype ubiquitin ligase that mediates degradation via the ubiquitin−proteasome pathway. 45 Together, these findings indicate that Nrf1 plays a central role in upregulating the proteasome system through an ERAD-dependent feedback loop. Currently, however, the mechanism that regulates Nrf1 expression in vivo is poorly understood. To determine the function of Nrf1 in the brain, mice with a late-stage Nrf1 deletion in neuronal cells were generated. Loss of Nrf1 leads to impaired proteasome function and neurodegeneration. These findings reveal that Nrf1 is a key transcriptional regulator required for the expression of proteasome genes in neurons and suggest that perturbations in Nrf1 function may contribute to the pathogenesis of neurodegenerative diseases. 46 In addition, another Nrf1-related transcription factor, Nrf2, which is responsible for the basal and inducible expression of numerous detoxifying and antioxidant genes, is also reported to partially control the upregulation of proteasome genes, 47, 48 but the details are not well understood.
Physiology and Pathology in
Cell-mediated Immunity
To date, expanding knowledge on the ubiquitin−proteasome pathway (UPS) clearly indicates that the UPS is involved in multiple physiologically important cellular processes, such as developmental programs and environmental responses. Consequently, it is evident that failures in the UPS can cause pathologically intractable diseases. In addition, emerging evidence, based mainly on murine genetic analysis of regulatory subunits in addition to catalytic subunits, points to the physiology and pathology of the proteasome in vivo (reviewed by Tanaka et al. 14 ) . In this section, I discuss the immunological roles of the proteasome, focusing on its diversity, but I will not include other pathophysiological roles that have been already comprehensively overviewed. 14 
Immunoproteasome
The proteasome processively degrades target proteins to generate oligopeptides ranging in length from 3 to 15 amino acids. In vertebrates, the oligopeptides produced by the CP can be used as antigenic peptides [also often called major histocompatibility complex (MHC) class I ligands or cytotoxic T lymphocyte (CTL) epitopes] for MHC class I molecules (reviewed by Tanaka and Kasahara 49 and Rock et al. 50 ). MHC class I displays intracellular/endogenous antigens to CD8 + killer cells or CTLs, whose T-cell receptors recognize the MHC−peptide complex with high fidelity, and subsequently activate T cells to initiate cell-mediated immunity. In 1994, Rock and Goldberg's group reported that proteasome inhibitors block the generation of peptides presented on MHC class I molecules, indicating for the first time that the proteasome is an antigen-processing enzyme in the MHC class I pathway and solving a long-term mystery in immunology. 51 Subsequently, in 1994, we found that interferon-γ (IFN-γ; also called type II IFN or immuno-cytokine) induces the expression of β1i, β2i, and β5i catalytic subunits, which are structurally related to β1, β2, and β5 of the standard proteasome, respectively, with more than 50% identity (Fig. 2, middle panel) . The standard proteasome is constitutively expressed in all cells and tissues, but expression decreases on administration of IFN-γ. The expression of these three unique subunits leads to the formation of a unique CP isoform in which the catalytic subunits β1, β2, and β5 are replaced with β1i, β2i, and β5i, respectively, as a result of the response to IFN-γ. In 1994, we proposed that the IFN-γ-inducible proteasome isotype should be called the "immunoproteasome" to emphasize its specialized roles as a dedicated antigen-processing enzyme in cell-mediated immunity 49, 52, 53 (Fig. 2, middle panel) . The immunoproteasome can be generated by preferential assembly mechanisms, but it does not replace mature proteasomes. In the preferential assembly mechanism, propeptides from immunoproteasomal subunits contribute to their preferentially selective incorporation into the β-ring as intramolecular chaperones. [54] [55] [56] The chymotrypsin-like activity of the proteasome is thought to be important for the production of antigenic peptides with high affinities for MHC class I clefts, which serve as peptide-binding pockets. Interestingly, the immunoproteasome has higher chymotrypsin-like activity than the standard proteasome. 54, 57 The vertebrate proteasome system has considerable diversity among the catalytic subunits, which have evolved during the acquisition of adaptive immunity. 49 Mice lacking genes that encode immunoproteasome subunits (i.e., β1i, β2i, or β5i) display defective antigen processing and consequently have compromised immune responses (review details in Sijts and Kloetzel 58 ). These initial studies emphasized the immunological importance of this immunoproteasome in mice. Further studies using β1i, β2i, or β5i double and/or triple KO mice more convincingly addressed the pivotal roles of these immunosubunits in the production of MHC class I peptides and showed that the immunoproteasome plays a much more important role in antigen presentation than was previously thought. 58, 59 A recent surprising discovery established that the immunoproteasome suppresses cell death resulting from IFN-induced oxidative stress by blocking the accumulation of harmful protein aggregates, indicating that the immunoproteasome has unexpected fundamental roles other than a specific role in the production of MHC class I ligands. 60 Efficient clearance of these aggregates by the immunoproteasome helps preserve cell viability under IFN-induced oxidative stress conditions. Other evidence has also indicated that the immunoproteasome plays important roles beyond the antigen-processing pathway. One landmark study determined that a specific inhibitor of β5i, namely PR-957, blocked β5i-mediated presentation of MHC class I-restricted antigens. 61, 62 Interestingly, the same inhibitor resulted in profound reductions in cellular infiltration, cytokine production, and autoantibody levels, thereby attenuating the progression of experimental arthritis. These studies highlight a unique role for β5i in controlling pathogenic immune responses and provide a therapeutic rationale for targeting β5i in autoimmune disorders.
More recently, several groups independently reported that a homozygous missense mutation in the β5i gene (PSMB8) causes an autoinflammatory disorder named Nakajo−Nishimura syndrome (NNS) that is inherited in an autosomal recessive fashion and is clinically characterized by autoinflammation and lipodystrophy. 63, 64 It is likely that the G201V and G197V mutations in β5i are in close proximity to the catalytic threonine residue and disrupt the β-sheet structure. These β5i mutants are not efficiently incorporated during immunoproteasome bio-genesis, resulting in assembly defects and reduced activities of all proteasomal peptidases within cells expressing immunoproteasomes. The reduced proteasomal activities cause an accumulation of ubiquitylated and oxidized proteins due to defective proteasome assembly, leading to stress-dependent activation of the p38 MAP kinase pathway. Consequently, high IL-6 expression is detected in the skin and B cells of NNS patients. These changes may account for the exaggerated inflammatory response and periodic fever observed in these patients. On the other hand, downregulation of β5i inhibited the differentiation of murine and human adipocytes in vitro. These findings identify β5i as an essential component and regulator not only of inflammation but also of adipocyte differentiation, indicating that immunoproteasomes have pleiotropic functions in maintaining the homeostasis of a variety of cell types. Until recently, NNS was thought to be a local disease endemic to Japan, but affected patients with similar, but not identical, mutations in β5i have been found in pedigrees from Portugal and Mexico with panniculitis-induced lipodystrophy (JMP) syndrome and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, 65, 66 indicating that β5i mutations are a worldwide phenomenon.
Thymoproteasome
The thymus is the organ where T lymphocytes are generated. On entering the thymus, T-lymphoid progenitor cells are translocated in the outer region of the cortex where they begin expressing CD4, CD8, and αβ T-cell antigen receptor (TCR) to initiate their development into T lymphocytes; the thymocytes are referred to as CD4 + CD8 + (double positive, DP) T cells. DP T cells that interact via TCR with the peptide/MHC complex in the cortical thymic epithelial cells (cTEC) are selected for survival or death depending upon the TCR-peptide/MHC interaction. DP T cells that receive weak TCR signals are induced to survive and continue development into mature T lymphocytes; i.e., CD4 + CD8 − or CD4 − CD8 + single positive (SP) T cells. These processes of TCR-mediated developmental promotion of DP T cells to SP T cells are referred to as "positive selection." On the other hand, DP T cells that receive strong TCR signals are destined to die, a process termed "negative selection" (see below for details). Whereas the molecular mechanisms underling negative selection have been studied extensively, the mechanisms of positive selection remain poorly understood.
Another landmark study was the discovery of the thymoproteasome as a unique enzyme involved in the formation of the MHC class I-restricted CD8 + T-cell repertoire during thymic positive selection. In 2007, we serendipitously identified a previously unrecognized catalytic subunit with an overall sequence that is highly similar to β5 and β5i, suggesting that the subunit belongs to the same β5 family of proteins. 67 Interestingly, the subunit was expressed exclusively in the mouse thymic cortex, particularly in cTECs. Because of its unique expression, the subunit was designated β5t. This new subunit was also determined to have thymus-specific expression in humans. 68 The molecular mechanism underlying thymusspecific expression of β5t is unknown, but it is plausible that the transcriptional factor Foxn1 is responsible for this unique expression because β5t expression is impaired in the thymus of Foxn1-deficient nude mouse embryos. 69 Intriguingly, β5t and the immunosubunits β1i and β2i, but not their standard counterparts β1 and β2, are incorporated into the vertebrate-specific alternative 20S proteasome, which we named the "thymoproteasome" because of its thymus-specific expression (Fig. 2, middle panel) . 67 As mentioned above, although the chymotrypsin-like activity of proteasomes plays an essential role in MHC class I-restricted antigen processing, the incorporation of β5t, instead of β5 or β5i, into the proteasome markedly reduces this activity, strongly indicating that the thymoproteasome may alter the quality of the peptide repertoire. A superimposed structural model revealed that this reduced activity is caused by changes in residues near the catalytic site. The residues near the active sites of both β5 and β5i are hydrophobic, which allows them to access hydrophobic peptides easily, but those of β5t are hydrophilic and antagonize the chymotryptic activity (Fig. 2, right panel) .
To examine the in vivo role of β5t and the thymoproteasome, we generated β5t-KO mice, and these displayed major defects in thymic CD8 + T-cell development. There were no obvious abnormalities in thymic architecture, including size and histology, indicating that β5t is not essential for the differentiation and proliferation of cTECs; specifically, there were no obvious changes in the numbers of cTECs, CD4 + CD8 + (co-receptors of TCR) DP thymocytes, CD4 + T-cell populations, or of any other examined cell type, including Aire-expressing medullary thymic epithelial cells. In addition, β5t-deficient mice did not have altered negative selection or impaired T-cell responses. In contrast, the number of immunoproteasomes increased at the expense of thymoproteasomes (i.e., β5t changed to β5i in the thymus cortex), which could be responsible for the production of MHC ligands that could not fulfill positive selection. This finding is consistent with the unchanged expression levels of MHC class I in β5t-deficient cTECs, which indicates that most MHC class I molecules on the cTEC surface are associated with peptides irrespective of the β5t deficiency because empty MHC molecules are extremely unstable and rapidly degraded via the endocytotic pathway. These results emphasize the role of β5t in the development of the MHC class I-restricted CD8 + T-cell repertoire during thymic selection, indicating that thymoproteasome-generated peptides are responsible for the positive selection of developing thymocytes. 67 During positive selection, DP cells that interact with self-peptide-MHC complexes on cTECs with sufficiently modest avidity [i.e., affinity (MHC−TCR interaction) × density (surface MHC levels)] are rescued from intrathymic death and induced to differentiate into CD4 + or CD8 + SP thymocytes. In contrast, DP cells that have high affinity or avidity interactions with self-peptide-MHC complexes are eliminated through apoptosis, a process referred to as negative selection. 70 In addition, thymocytes that lack functional T-cell receptors also undergo apoptosis, a process called null selection. These selection mechanisms are commonly referred to as thymic education of the immune system. To date, however, the mechanisms by which cTECs provide specialized signals for positive selection remain poorly understood. Considering that the proteasome is essential for the production of MHC class I ligands and that β5t specifically attenuates proteasomal chymotryptic activity without altering the caspase-and trypsin-like activities, as mentioned above, it is possible that the thymoproteasome in cTECs predominantly produces MHC class I ligands with moderate avidity rather than high-affinity ligands, which would support the positive selection hypothesis that was proposed many years ago. 70 Although the positive selection hypothesis has been considered unreliable for more than a decade because of the lack of solid evidence, the discovery of the thymoproteasome will enhance our understanding of positive selection mechanisms in the thymus.
Until the discovery of the thymoproteasome, little was known about how self-peptides displayed in the thymus contribute to the development of immunocompetent and self-protective T cells. In contrast, the role of thymic selfpeptides in eliminating self-reactive T cells and thereby preventing autoimmunity is well established. To date, we know that cTECs display thymoproteasome-specific peptide−MHC class I complexes that are essential for the positive selection of the major and diverse repertoire of MHC class I-restricted T cells. CD8 + T cells generated in the absence of thymoproteasomes displayed a markedly altered T-cell receptor repertoire that was defective in both allogeneic and antiviral responses. 71 Thus, the thymoproteasome is required to generate optimal cellularity of CD8 + T cells and plays an essential role in the development of the MHC class I-restricted CD8 + T-cell repertoire during thymic positive selection. 72 We previously proposed a chromosomal duplication hypothesis to explain the emergence of IFN-γ-regulated subunits. We compared the sequences of the β-type subunit genes of the standard and immunoproteasome to show that each subunit pair is derived from a common ancestor gene. 49 The basic assumption in this model is that all the IFN-γ-regulated immunosubunits emerged simultaneously as a result of a duplication of the MHC region during genome-wide duplication. As is also the case for immunoproteasome genes, the β5t gene (officially named PSMB11) appears to result from a modification and duplication of existing nonimmune genes, such as β5, and this duplication may have been instrumental in the emergence of the adaptive immune system. Intriguingly, β5t is encoded by an intronless gene, in contrast to the β5 and β5i genes, which both contain three exons. Curiously, the β5t gene is adjacent to the PSMB5 gene encoding the β5 subunit of the standard proteasome in mammals and lower vertebrates, such as reptiles, amphibians, and teleost fish. This fact suggests that the PSMB11 gene arose from a tandem duplication from the evolutionarily more ancient PSMB5 gene and then lost introns evolutionarily by an unknown mechanism. 73 
Outlook
In this review, we briefly discussed the structure−function relationship of the proteasome with particular emphasis on the pathophysiological roles of the core proteasome machinery of the CP and of the RP, the main regulator of the CP. However, it is important to note that there are other regulators, such as PA28 and PA200, indicating that there are additional multifaceted mechanisms that regulate the proteasome system (for details, see Tanaka et al, 14 Tanaka and Kasahara, 49 and Stadtmueller and Hill 74 ). Over the past 25 years, the divergent functions of the proteasome have been comprehensively elucidated in the life sciences. However, the incidences of intractable diseases such as cancers, infectious diseases, and neurodegenerative diseases have recently been increasing, especially in the elderly population. In this context, it is plausible that dysfunctions in the proteasome machinery are a common abnormality that partially contributes to these diseases. Thus, the proteasome has been extensively studied in both basic and clinical fields using multipronged approaches.
